Sweet Tidings For LXRX, CYAD To Report Data In Q4, D-Day For FOMX Today

Foamix Pharmaceuticals Ltd. (FOMX) is all set to report phase II results of FMX103, which is being tested for the treatment of papulopustular rosacea, today.

from RTT - Biotech http://ift.tt/2cxq8Sj
via IFTTT